Literature DB >> 8033414

Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations.

F Silvestris1, P Cafforio, F Dammacco.   

Abstract

This study was addressed to explore the reactivity of natural anti-idiotypes from commercial lots of immunoglobulins to several idiotypes (Ids), usually expressed by anti-DNA molecules in lupus nephritis. Eleven intravenous immunoglobulin (IVIG) preparations and nine (three polyvalent and six hyper-immune) intramuscular IgG were investigated for specific content of anti-DNA, anti-F(ab')2 and antibodies reacting with several anti-DNA IgG Ids. Two samples (nos 6 and 11) showed high reactivity with allogeneic F(ab')2 and with F(ab')2 of myeloma proteins bearing the anti-DNA Id 3I+ and the 8.12+. Since both 3I and 8.12 Id markers are known to characterize pathogenic anti-DNA IgG in systemic lupus erythematosus (SLE), anti-Id antibodies to these markers were obtained by absorbing the IVIG samples nos 6 and 11 to Sepharose columns coupled with pooled F(ab')2 fragments of 3I(+)-F4(+)-8.12(+)-myeloma proteins. Inhibition experiments showed that anti-8.12 Id-eluted IgG induced a selective suppression of the DNA-reactive antibodies derived from patients with active lupus nephritis to their substrate, suggesting the involvement of 8.12+ molecules in the SLE glomerular damage. Since 8.12+ anti-DNA are nephritogenic antibodies, the occurrence of anti-8.12+ Id in commercial IVIG may be of potential therapeutic relevance in modulating the pathogenic SLE Id network. Previous variable results of IVIG treatment in SLE, such as resolution of proteinuria or worsening nephritis, could be related to variable enrichment of different lots of IVIG in suppressive anti-pathogenic Id antibodies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033414      PMCID: PMC1534792          DOI: 10.1111/j.1365-2249.1994.tb06573.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

2.  What is wrong with the failing heart?

Authors:  J T Willerson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

3.  Lupus serum and normal human serum contain anti-DNA antibodies with the same idiotypic marker.

Authors:  M P Madaio; A Schattner; M Shattner; R S Schwartz
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

4.  Idiotype restriction in murine lupus; high frequency of three public idiotypes on serum IgG in nephritic NZB/NZW F1 mice.

Authors:  B H Hahn; F M Ebling
Journal:  J Immunol       Date:  1987-04-01       Impact factor: 5.422

5.  Familial systemic lupus erythematosus. Presence of a cross-reactive idiotype in healthy family members.

Authors:  R Halpern; A Davidson; A Lazo; G Solomon; R Lahita; B Diamond
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

6.  Heparan sulfate--rich anionic sites in the human glomerular basement membrane. Decreased concentration in congenital nephrotic syndrome.

Authors:  R L Vernier; D J Klein; S P Sisson; J D Mahan; T R Oegema; D M Brown
Journal:  N Engl J Med       Date:  1983-10-27       Impact factor: 91.245

7.  In vitro inhibition of anti-DNA producing cells from systemic lupus erythematosus patients by autologous anti-F(ab')2 antibodies.

Authors:  F Silvestris; R C Williams; M A Frassanito; F Dammacco
Journal:  Clin Immunol Immunopathol       Date:  1987-01

8.  Treatment of adult patients with idiopathic thrombocytopenic purpura with intravenous immunoglobulin: effects on circulating T cell subsets and PWM-induced antibody synthesis in vitro.

Authors:  F Dammacco; G Iodice; N Campobasso
Journal:  Br J Haematol       Date:  1986-01       Impact factor: 6.998

9.  In vitro modulation of anti-DNA secreting peripheral blood mononuclear cells of lupus patients by anti-idiotypic antibody of pooled human intravenous immune globulin.

Authors:  M Evans; N I Abdou
Journal:  Lupus       Date:  1993-12       Impact factor: 2.911

10.  Studies of anti-F(ab')2 antibodies and possible immunologic control mechanisms in systemic lupus erythematosus.

Authors:  F Silvestris; A D Bankhurst; R P Searles; R C Williams
Journal:  Arthritis Rheum       Date:  1984-12
View more
  6 in total

Review 1.  Toward molecular targeting with specific intravenous immunoglobulin preparation.

Authors:  Miri Blank; Israel Nur; Orgad Toub; Anabel Maor; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; L Ashkenazi; Y Milner; M Frusic-Zlotkin; G J Anhalt; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

3.  Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific?

Authors:  F Perosa; R Rizzi; V Pulpito; F Dammacco
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

4.  Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.

Authors:  I Krause; M Blank; Y Shoenfeld
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

5.  Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; A S Payne; G J Anhalt; C Avivi; I Barshack; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

6.  Intravenous immunoglobulin therapy of lupus pneumonitis.

Authors:  G Chetan; S Mahadevan; Kikon Sulanthung; P Narayanan
Journal:  Indian J Pediatr       Date:  2007-11       Impact factor: 1.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.